close

Windlas Biotech Ltd

Know More
NSEBSE

350.359.40 (2.76%)

03:56 PM,26th Sep 2023

350.105.10 (1.48%)

04:01 PM,26th Sep 2023

BSE : 543329

NSE : WINDLAS

Sector : Health care

ISIN Code : INE0H5O01029

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Sep 26 2023 | 04:01 PM IST

Market Cap (₹ Cr)

745

Turnover (₹ Cr)

0.16

Volume (Shares)

45543

Face Value

5

52-WK High

420.90

52-WK High Date

18 Aug 2023

52-WK Low

212.00

52-WK Low Date

25 Oct 2022

All Time High

452.00

All Time High Date

16 Aug 2021

All Time Low

203.25

All Time Low Date

20 Jun 2022

Windlas Biotech Ltd

Windlas Biotech Ltd (formerly known as Windlas Biotech Private Limited) was incorporated in the year 2001. The Company provides pharmaceutical development services large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world.The company has state-of-the-art manufacturing plant facilities located in Dehradun Uttarakhand India. It also has a sales force and distribution network spread across 14 states. The company market its own manufactured authentic nutraceutical pharmaceutical and Ayurvedic products to serve the semi-urban and rural communities at affordable prices. Apart from this the company has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports.The company provides a comprehensive range of CDMO services ranging from product discovery product development licensing and commercial manufacturing of generic products including complex generics in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety efficacy and cost. In addition to this it sells its own branded products in the trade generics and OTC markets as well as export generic products to several countries. Moreover the company has significant experience in developing and manufacturing generic fixed dose combinations. Its focus has currently been in launching new complex generic products in the chronic therapeutic category linked to lifestyle related disorders.The company focused on developing and launching new complex generic products containing APIs which are difficult to handle or formulate. It needs pairing with a device to make a drug-device combo primarily in solid and liquid pharmaceutical dosage forms to provide specialized capabilities to customers especially for high potency controlled substances and low-solubility products. Further the development and manufacturing of complex generic products typically involves a higher degree of expertise/ trained manpower and utilizes higher overall process times. Its complex generic products portfolio primarily comprises fixed dosage combinations fixed dosage plus modified release combinations customized generics and chewable or dispersible. To conclude the company has introduced high quality systems across its manufacturing facilities that cover the full product lifecycle from process innovation and R&D through the stages of process development manufacturing sales and supply chain to the customer evaluation of products as well as management systems for ensuring consistent quality efficacy and safety of products. And hence forth the company identifies and approves multiple vendors to source the raw materials pursuant to robust vendor assessment in addition to the suppliers approved by its customers.

Windlas Biotech Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

745

EPS - TTM (₹) [S]

21.11

P/E Ratio (X) [S]

1.85

Face Value (₹) 5
Latest Dividend (%)80.00
Latest Dividend Date 05 Sep 2023
Dividend Yield (%) 1.12
Book Value Share (₹) [S]189.39
P/B Ratio (₹) [S]1.85
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
ICICI Pru Smallcap Fund (G) 41.11 1100485 0.59
ICICI Pru Smallcap Fund (IDCW) 41.11 1100485 0.59
ICICI Pru Smallcap Fund - Direct (G) 41.11 1100485 0.59
ICICI Pru Smallcap Fund - Direct (IDCW) 41.11 1100485 0.59
ICICI Pru P.H.D Fund (G) 32.04 857651 1.01
ICICI Pru P.H.D Fund (IDCW) 32.04 857651 1.01
ICICI Pru P.H.D Fund - Direct (G) 32.04 857651 1.01
ICICI Pru P.H.D Fund - Direct (IDCW) 32.04 857651 1.01
UTI-Healthcare Fund (G) 8.06 215611 1.04
UTI-Healthcare Fund - Direct (G) 8.06 215611 1.04

Load more

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

342.95

353.00

Week Low/High

333.60

374.00

Month Low/High

333.60

396.00

Year Low/High

212.00

421.00

All time Low/High

203.15

452.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week-2.15%-2.21%-2.44-2.33%
1 Month-3.70%-3.63%1.632.07%
3 Month16.38%15.65%4.715.35%
6 Month46.84%46.59%14.6316.05%
1 Year51.47%51.18%13.5113.49%
3 Year%%76.3877.96%

Financials

Graph
Table

Bulk/ Block

ALL
NSE
BSE
ALL
BUY
SELL
DateClient NameExchangeTransactionQuantityPrice
10-08-2023GRAVITON RESEARCH CAPITAL LLPNSEBUY125706377.40
10-08-2023GRAVITON RESEARCH CAPITAL LLPNSESELL125706377.57
07-07-2023GRAVITON RESEARCH CAPITAL LLPNSEBUY127836333.97
07-07-2023GRAVITON RESEARCH CAPITAL LLPNSESELL127836334.53
20-09-2021KUBER INDIA FUNDNSESELL113468379.73
16-08-2021ALPHAGREP SECURITIES PRIVATE LIMITEDNSEBUY116009425.28
16-08-2021ALPHAGREP SECURITIES PRIVATE LIMITEDNSESELL116009425.42
16-08-2021ICICI LTD TRADING A/CNSESELL122350417.62

Peer Group Comparison

NamePrice(In Rs)Chg(%)Mkt Cap(Rs Cr)Sales(Rs Cr)Profit(Rs Cr)EPS(Rs)P/E(x)

Shareholding Pattern

Jun 2023
Archive
CategoryShare(%)
Promoter62.82
Financial Institutions Banks0.04
Foreign Institutional Investors0.80
Insurance Companies0.00
Mutual Funds Uti10.51
Other Institutional Investors0.98
Indian Public22.01
Others Non Institutional Investors2.84
Custodians0.00

Corporate Action

Announcement DatePurposeFromToRemarks
Data Not Found

Price History

Search for Price History

DateOpenHighLowCloseSharesTrades
Data Not Found

Load more

Company Info

Company Information

Registered Office: 40/1 Mohabewala Industrial, Area,Dehradun,Uttarakhand-248110 Ph: 91-135-6608000

Email:grievance@windlasbiotech.com

URL:http://www.windlasbiotech.com